Articles tagged with Melanoma
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
A phase I trial found that combining fecal transplants with immunotherapy is safe and shows promise in improving clinical responses in 65% of patients. The study used healthy donor microbiome to enhance immune system attack on cancer, offering a new paradigm shift in melanoma treatment.
A new study from Sanford Burnham Prebys identified a protein called NR2F6 that helps melanoma cells evade the immune system, but also promotes anti-tumor immunity when targeted. The researchers hope to develop new drugs that can block this protein's activity, potentially doubling the effectiveness of immunotherapy for melanoma patients.
Scientists found that CXCL13-mediated recruitment of B cells helps predict response to immunotherapy treatment. This cooperation between T cells and B cells is associated with improved survival in patients treated with immunotherapy.
A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
A new study reveals that antibody-producing B cells in patients with melanoma may be defective, leading to ineffective responses against the disease. The research finds that active B cells accumulate at the edge of tumors and gather in small groups, carrying specific antibody features that react with T cells and other immune cells.
Researchers at Karolinska Institutet have identified how memory killer cells are formed and found a correlation between their presence in cancer tissue and improved survival rates in people with melanoma. The study suggests that harnessing the potential of these cells could lead to more effective immunotherapy.
Scientists from Brigham and Women's Hospital have developed a new immuno-therapeutic approach using twin stem cells that can target brain metastatic melanomas. The therapy, which uses an engineered 'twin stem cell model,' activates the immune system to suppress tumor growth and prolong survival in representative preclinical models.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
Researchers at Sanford Burnham Prebys have found a way to revive exhausted T cells, which are crucial for destroying cancerous cells. The new approach targets PSGL-1 protein and slows down T cell exhaustion, significantly reducing tumor growth in mice with immunotherapy-resistant melanoma.
Researchers analyzed genetic changes in organs of recently deceased patients with metastatic cutaneous melanoma to understand how the disease spreads and evolves. They found that cancer cells take advantage of specific organ environments, pointing to the need for distinct treatment approaches.
A new class of immunotherapy has shown promising results in targeting and treating the most aggressive form of skin cancer, malignant melanoma. The study developed an IgE antibody that activates the immune response to fight cancer and slows melanoma growth in mice.
Research suggests that patients with advanced melanoma who receive immunotherapy medications may benefit from maintaining normal vitamin D levels. The study found a favorable response rate in 56% of patients with normal baseline vitamin D levels, compared to 36% with low levels.
A new MYC inhibitor, Omomyc, has shown promising preclinical results in reducing melanoma tumor growth and metastatic capacity by halting the transcription of genes implicated in cell growth and proliferation. The study demonstrates a good prognostic gene signature in melanoma patients with this approach.
A new patient-centered approach identifies melanoma patients most likely to benefit from sentinel lymph node biopsy, offering a more accurate and cost-effective method for selecting patients. The study found that adopting a 10% cutoff for positivity rates could help identify patients best eligible for the procedure.
The USPSTF finds the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer. Skin cancer is the most commonly diagnosed cancer in the U.S., with melanomas causing the most skin cancer deaths.
A recent study found that immunotherapy alone resulted in a 89% favorable treatment response rate for patients with desmoplastic melanoma. This suggests that combination therapies may not be necessary for these patients, reducing the risk of toxicity.
A recent clinical trial found that nearly 90% of patients with unresectable desmoplastic melanoma responded to treatment with pembrolizumab. The immunotherapy drug showed impressive results in both treatable and inoperable cases, suggesting a promising treatment option for this rare form of skin cancer.
A new vaccine type, mRNA-4157/V940, added to immunotherapy significantly reduced melanoma recurrence and death rates. The combination was found to be effective in 22.4% of patients compared to 40% without the vaccine.
A study published in Cancer Cell found that prior treatments, such as CTLA-4 blockade, modify the response to anti-PD-1 checkpoint blockade therapy. The research analyzed data from over 500 patients and identified key factors associated with treatment response. This finding may help scientists create more precise future treatments.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
Researchers analyzed autopsies of 14 patients with advanced melanoma, finding that changes to tumor DNA can cause resistance to treatment. The study sheds light on the final stages of cancer and may lead to new treatments for patients with advanced disease.
Scientists have developed a new vaccine delivery method using powdered vaccines and a system driven by compressed gas, called MOF-Jet. The device can deliver therapeutics against cancer and other diseases in a relatively painless way, eliminating the need for needles and potentially reducing pain.
Researchers at Moffitt Cancer Center have discovered a combination strategy that targets the STING signaling pathway, resulting in improved antitumor activity. Inhibiting methylation increases STING expression and activates immune cells, leading to enhanced antitumor immunity.
Researchers from China have identified inosine as a potential broad-spectrum anti-inflammatory agent that improves survival in mice infected with SARS-CoV-2. The study also highlights TBK1 as a promising target for inhibiting cytokine storms and mitigating acute inflammatory lung injury.
A new surgical therapy has proven effective in treating melanoma in the eye that has spread to the liver, with 40% of patients experiencing tumor shrinkage, and offers a promising alternative to current treatments.
A study found that individuals with a history of atopic diseases, such as allergic asthma or rhinitis, had significantly lower rates of melanoma and skin cancer compared to non-atopic individuals. The risk of melanoma was up to 50% lower in atopic patients, and the overall risk of skin cancer was also reduced.
A phase 2 clinical trial shows that treating resectable stage 3 and 4 melanoma patients with pembrolizumab both before and after surgery greatly improves outcomes compared to pembrolizumab given only after surgery. This approach resulted in significantly longer event-free survival rates.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
Researchers found that adding immunotherapy before surgical removal of stage III-IV melanoma significantly improved event-free survival compared to standard-of-care treatment. The study showed that neoadjuvant therapy is superior to the same therapy given in the adjuvant setting.
Researchers found that combining a chemical blocker of immune cell exit with immunotherapy stopped melanoma tumor enlargement in over half of mice tested. The study showed that T cells circulate out of tumors, reshaping scientific views of tumor immunology.
Researchers have discovered that cancer patients who don't respond to immunotherapy often lack CD5+ dendritic cells, which are essential for effective T cell activity. Boosting these cells may help more patients benefit from immunotherapy.
A study by University of Gothenburg researchers found a significant association between methotrexate use and an increased risk of basal cell carcinoma, squamous cell carcinoma, and cutaneous malignant melanoma. The study suggests that higher doses of methotrexate may increase the risk of SCC and BCC, while no dose-response relationship...
Researchers at the University of South Australia are developing new biomarkers to improve melanoma detection and avoid delayed treatment. The current markers used in clinical practice are not always sensitive or specific, leading to fatal consequences if cancerous cells are missed.
Researchers identified a subset of mutations within tumor mutation burden that remain persistent and visible to the immune system, increasing likelihood of response to immunotherapy. This finding enables clinicians to more accurately select patients for clinical trials or predict clinical outcomes with immune checkpoint blockade.
Moffitt researchers found that administering oral L-fucose increases TILs, reduces tumor growth, and enhances immunotherapy efficacy in animal models. Higher L-fucose levels in melanomas are associated with less aggressive disease and better responses to therapy.
Researchers discovered that 15-deoxy-prostamide-J2 induces ER stress-mediated apoptosis selectively in tumor cells, reducing melanoma growth. The molecule activates PERK, IP3R, and the mitochondrial permeability transition pore, leading to cell death.
A new classification system, MPATH-Dx Version 2.0, has been developed to simplify diagnoses of melanocytic skin lesions. The system categorizes lesions into four classes, providing guidance on treatment and surveillance for patients.
A new study found that COVID-19 primarily affected patients with a moderate to critical course, often with comorbidities, whereas many had mild courses despite metastatic melanoma and systemic therapy, recommending continued treatment whenever possible.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Regular use of vitamin D supplements was associated with a significantly reduced risk of melanoma and better skin cancer classification compared to non-users. However, the study did not find a significant association between vitamin D use and other skin changes or severity of photoaging.
A new study has identified a protein called LAP1 that makes melanoma cells more aggressive by changing their nucleus shape. The protein allows cancer cells to migrate and spread throughout the body, leading to poor outcomes in patients.
A new multidrug treatment combining pembrolizumab and all-trans retinoic acid has proven effective in treating stage IV melanoma, with an overall response rate of 71% and a one-year overall survival rate of 80%. The study's results are promising for patients who have failed traditional immunotherapy.
The TIL trial has demonstrated that cell therapy using patient's own immune cells is an extremely powerful immunotherapy for metastatic melanoma, with significant shrinkage of metastases in half of patients. Progression-free survival after six months was 53%, significantly better than standard immunotherapy with ipilimumab.
The study suggests a significant decrease in US melanoma mortality rates, thanks to the availability of effective therapies and new pharmacological treatments. These findings are encouraging and support the continued development of such therapies.
Researchers at the University of Pittsburgh School of Medicine have discovered a genetic link between melanoma tumors and telomere maintenance, which could lead to new treatments for the disease. The study found that mutations in the TPP1 gene stimulate telomerase activity, promoting long telomeres that enable cancer cells to divide in...
A study has identified a subset of early-stage melanoma patients with almost no risk of death, potentially contributing to overdiagnosis. The researchers used cancer registry data and developed models to identify patients with a very low risk of mortality.
A team from Massachusetts General Hospital developed an AI-based method to predict which patients with early-stage melanoma are most likely to experience a recurrence. Machine learning algorithms extracted predictive signals from clinicopathologic features, including tumor thickness and rate of cancer cell division.
A new method of modifying our immune system has been demonstrated in a study published in Advanced Science, which could help treat skin cancer.
A Phase II study found that the combination of relatlimab and nivolumab was safe and completely cleared all viable tumor in 57% of patients with stage III melanoma before surgery. The overall pathologic response rate was 70%, with no grade 3 or 4 immune-related adverse events reported.
The study analyzed DNA methylation in skin tumor samples, revealing correlations between changes in proteins regulating the organism and prognosis. The results identified potential markers of patient survival and suggested a new route for understanding melanoma subtypes.
Researchers found that high PERK activity correlates with poorer outcomes and lower anti-tumor immune cells in patients with melanoma. Inhibition of PERK promoted a type of cell death called paraptosis, which involved trafficking of immune cells to tumors and matured dendritic cells triggering anti-tumor T cell immunity.
A recent clinical trial found that patients with advanced melanoma who received immunotherapy first had a 20% higher two-year overall survival rate compared to those who initially got targeted therapies. The study also showed improved progression-free survival rates for those on immunotherapy.
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Tel Aviv University researchers discovered that skin cancer cells interact with astrocytes in the brain, promoting metastasis. By inhibiting this interaction using existing treatments, they delayed the spread of melanoma to the brain by 60-80%. This breakthrough has implications for treating advanced-stage melanoma.
Researchers found mutations in leukocyte and T-cell proliferation regulation processes that contribute to ICI treatment response and resistance. The study provides a framework to develop predictors for melanoma, potentially enhancing responses and increasing patient numbers.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.